Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Treatments in Oncology



  • Clinical Briefs in Primary Care Supplement

  • Extranodal Marginal Zone Lymphoma

    The term marginal-zone lymphoma (MZL) refers to three distinct but closely related lymphoprolferative disorders: mucosa-associated lymphoid tissue (MALT) lymphoma (extranodal MZL), splenic MZL, and nodal MZL.
  • Population Screening for the Early ID of Prostate Cancer

    To assess whether screening for prostate cancer reduces prostate-specific mortality, a population-based, randomized, controlled trial for a random sample of men between the ages of 50 to 69 in a single city were screened every third year from 1987 to 1996. There was no significant difference in the rate of death from prostate cancer for the screened group compared to the control group after 20 years of follow-up.
  • CML Treatment in the Elderly: Imatinib Levels the Playing Field

    Older age is an adverse prognostic factor for chronic myeloid leukemia (CML) in the pre-tyrosine kinase era. The authors evaluated the influence of age on outcomes among 559 chronic-phase CML patients treated with imatinib.
  • Colorectal Adjuvant Chemotherapy: Timing Is Something

    In a retrospective review, delay beyond 60 days in initiating adjuvant chemotherapy after surgery for colorectal cancer was associated with poorer overall survival. Although factors such as surgical complications or the existence of comorbidities may explain the delays for some of the cases, other "administrative" factors, such as delays resulting from insurance authorizations or referral setbacks, are to be avoided, if at all possible.
  • Pharmacology Watch

    Two new drugs for treatment of hepatitis C; NSAIDs and myocardial infarction risk; AIM-HIGH clinical trial stopped; and FDA actions.
  • Pancreatic Cancer-Associated Thrombosis: Prevention and Treatment

    Deep vein thrombosis (DVT) and pulmonary embolus (PE) occur more frequently in patients with cancer, and the risk appears to vary by tumor type.
  • Denosumab vs Zoledronic Acid for Patients with Prostatic Bone Metastases

    In a Phase 3 trial comparing the recently introduced monoclonal antibody denosumab with zoledronic acid for the treatment of patients with prostate cancer metastatic to bone, the incidence of skeletal events including pathological fracture, radiation, skeletal surgery, or cord compression was delayed on average by more than 3 months for those treated with denosumab. Adverse events were comparable. Denosumab is administered subcutaneously and can be given to patients with renal insufficiency. Clinicians have become familiar with zoledronic acid in this setting, and it remains unclear whether its role as the standard approach will be supplanted.
  • Quality of Life to Predict Outcome for Older AML

    Investigators prospectively assessed quality of life in newly diagnosed AML patients 60 years and older using the EORTC QLC-C30 and QOL-E surveys. Among the 113 patients enrolled, 42.4% underwent intensive induction chemotherapy and 57.6% received palliative treatment. Self-rated quality of life did not correlate with physician-rated performance status or induction chemotherapy. Lower self-report functional status predicted higher mortality, even after adjusting for age, treatment, and comorbidity. Patient-reported quality of life may be an independent prognostic factor for AML outcomes.
  • Clinical Briefs in Primary Care Supplement